Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors

Liver Tumor Clinical Trial

Official title:

Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05211388
• Other study ID #: UCCC-GI-21-02
• Status: Recruiting
• Phase: N/A
• Start date: July 11, 2022
• Est. completion date: July 1, 2025

Study information

• Verified date: September 2023
• Source: University of Cincinnati
• Contact: UCCC Clinical Trials Office
• Phone: 513-584-7698
• Email: cancer[@]uchealth.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will comprise the first pilot clinical trial of 3D, ultrasound-based thermal ablation control using echo decorrelation imaging, directly testing the capability of this approach to ensure reliable tumor treatment. The purpose of this study is to determine the ability of ultrasound echo decorrelation to successfully predict complete ablation of human hepatocellular carcinoma, concomitant diseased liver, and metastatic liver cancer and to determine the potential of echo decorrelation imaging to provide effective real-time control of radiofrequency ablation (RFA) in liver tumors.

Description:

To rigorously test the feasibility of 3D echo decorrelation imaging to improve the reliability of clinical thermal ablation, decorrelation-controlled ablation will be assessed in a pilot treat-and-resect study. Patients previously scheduled for resection of metastatic liver tumors or benign liver tumors physiologically similar to hepatocellular carcinoma (HCC) (e.g., hepatocellular adenoma or focal nodular hyperplasia) will first undergo radiofrequency ablation (RFA) of their tumors, with real-time, 3D ultrasound echo decorrelation imaging of the treated region performed throughout each ablation. RFA will be performed in the same surgical procedure as the scheduled tumor resection, immediately prior to resection.

Patients will be enrolled in two arms, the first undergoing RFA controlled by the RFA generator using manufacturer-specified algorithms, and the second undergoing RFA with echo decorrelation imaging providing an additional stopping criterion. For both arms, 3D maps of ablation zones will be constructed from stained tissue sections and rigidly registered to volumetric ultrasound images using the known tumor position and orientation relative to the ultrasound image volume. Overall ROC curves for prediction of local treatment will be constructed using point-by-point comparison of 3D echo decorrelation images to the mapped ablation zone.

The ability of echo decorrelation to predict and control clinical thermal ablation of human liver tumors will be directly tested by assessing and statistically comparing outcomes of the two study arms, including ROC curves, ablation volume and rate, and conformity to planned ablation zones.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: July 1, 2025
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years.

2. Scheduled for resection of at least one confirmed primary or metastatic liver tumor with estimated diameter <5 cm at the University of Cincinnati Medical Center (UCMC).

3. Patients may have other disease (typically cirrhosis, hepatitis B or hepatitis C) for primary liver cancer patients and extrahepatic cancer (typically colorectal) for metastatic liver cancer patients.

4. Ability to understand and the willingness to sign the written research informed consent document for this study.

Exclusion Criteria:

1. The tumor for which the resection is scheduled is greater than or equal to 5 cm in diameter.

2. The tumor for which the resection is scheduled has received: prior ablation; chemoembolization; or, other treatment which in the opinion of the PI would disqualify a patient from participation.

3. Radiofrequency ablation (RFA) is contra-indicated for safety reasons in the opinion of the PI and/or clinical treatment team according to current standards of care (e.g., tumor adjacent to the heart, bowel, gall bladder, or bile ducts; impaired liver function; implanted cardiac devices).

4. Proceduralist assessment that research-specific radiofrequency ablation or intraoperative ultrasound imaging would cause substantial patient risk.

5. Pregnant women, prisoners, institutionalized individuals, or other individuals from vulnerable populations.

6. Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI.

Related Conditions & MeSH terms

• Liver Neoplasms
• Liver Tumor

Intervention

Procedure:
• RFA controlled using echo decorrelation imaging
The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion. The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume. To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points.
• RFA controlled using standard manufacturer-specified algorithms
The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.

Locations

Country	Name	City	State
United States	University of Cincinnati Medical Center	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ROC curves for local prediction of ablation of human liver tumors and concomitant diseased liver.	Receiver operating characteristic (ROC) curves for prediction of local ablation (dimensionless), constructed using point-by-point comparison of 3D echo decorrelation images to the mapped ablation zone (dimensionless, possible values between 0 and 1). Determined separately for each arm.	2 years
Primary	Area under ROC curves	Area under ROC curves for prediction of local ablation (dimensionless, possible values between 0 and 1). Determined separately for each arm.	2 years
Primary	Ablation volumes	Volumes (ml) of segmented ablation zones. Determined separately for each arm.	2 years
Primary	Thermal ablation rates	Ablation rates (ml/min), defined as ablation volumes (ml) divided by duration of radiofrequency ablation (min). Determined separately for each arm.	2 years
Primary	Conformity with planned ablation zone	Dice coefficients between segmented ablation volumes and targeted ablation zones (dimensionless, values between 0 and 1). Determined separately for each arm.	2 years